Ventyx Biosciences (VTYX) Stock Forecast & Price Target

Compare

785 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VTYX Analyst Ratings

Hold

0 Buy

8 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Ventyx

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VTYX Stock 12 Month Forecast

Average Price Target

$13.38

▼(-3.32% Downside)

Based on 8 Wall Street analysts offering 12 month price targets for Ventyx Biosciences in the last 3 months. The average price target is $13.38 with a high forecast of $14.00 and a low forecast of $9.00. The average price target represents a -3.32% change from the last price of $13.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.03,9.412307692307692,9.794615384615383,10.176923076923076,10.55923076923077,10.94153846153846,11.323846153846153,11.706153846153846,12.088461538461537,12.47076923076923,12.853076923076923,13.235384615384614,13.617692307692307,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.03,9.364615384615384,9.699230769230768,10.033846153846154,10.368461538461538,10.703076923076923,11.037692307692307,11.372307692307693,11.706923076923077,12.041538461538462,12.376153846153846,12.71076923076923,13.045384615384616,{"y":13.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.03,9.027692307692307,9.025384615384615,9.023076923076923,9.02076923076923,9.018461538461539,9.016153846153847,9.013846153846153,9.01153846153846,9.009230769230768,9.006923076923076,9.004615384615384,9.002307692307692,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.52,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.53,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.03,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$13.38

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen Rahimi

Piper Sandler

$21→$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences downgraded to Neutral from Overweight at Piper SandlerVentyx Biosciences downgraded to Neutral from Overweight at Piper Sandler

Edward Nash

Canaccord Genuity

$16→$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences downgraded to Hold from Buy at CanaccordVentyx Biosciences downgraded to Hold from Buy at Canaccord

Derek Archila

Wells Fargo

$14

Hold

1.16%

Upside

Downgraded

01/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ventyx Biosciences (NASDAQ: VTYX) and Kamada (NASDAQ: KMDA)

Emily Bodnar

H.C. Wainwright

$18→$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences downgraded to Neutral from Buy at H.C. WainwrightVentyx Biosciences downgraded to Neutral from Buy at H.C. Wainwright

Jeff Jones

Oppenheimer

$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences downgraded to Perform from Outperform at OppenheimerVentyx Biosciences downgraded to Perform from Outperform at Oppenheimer

Michael Yee

UBS

$20→$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences initiated with a Buy at UBSVentyx Biosciences initiated with a Buy at UBS

Sam Slutsky

LifeSci Capital

$14

Hold

1.16%

Upside

Downgraded

01/07/26

Hold Rating on Ventyx Biosciences Reflects Limited Upside Amid Eli Lilly All‑Cash Acquisition at $14 per Share

Alex Thompson CFA

Stifel Nicolaus

Hold

-34.97%

Downside

Assigned

01/07/26

Hold Rating Maintained on Eli Lilly’s Acquisition of Ventyx Biosciences Amid Limited Upside and NLRP3 Uncertainty

Kaveri Pohlman

Clear Street

$11

Buy

-20.52%

Downside

Initiated

09/30/25

Clear Street Initiates a Buy Rating on Ventyx Biosciences (VTYX)

Vikram Purohit

Morgan Stanley

Hold

―

Reiterated

06/17/25

Hold Rating for Ventyx Biosciences Amid Promising Early Data and Strategic Uncertainties

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen Rahimi

Piper Sandler

$21→$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences downgraded to Neutral from Overweight at Piper SandlerVentyx Biosciences downgraded to Neutral from Overweight at Piper Sandler

Edward Nash

Canaccord Genuity

$16→$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences downgraded to Hold from Buy at CanaccordVentyx Biosciences downgraded to Hold from Buy at Canaccord

Derek Archila

Wells Fargo

$14

Hold

1.16%

Upside

Downgraded

01/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ventyx Biosciences (NASDAQ: VTYX) and Kamada (NASDAQ: KMDA)

Emily Bodnar

H.C. Wainwright

$18→$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences downgraded to Neutral from Buy at H.C. WainwrightVentyx Biosciences downgraded to Neutral from Buy at H.C. Wainwright

Jeff Jones

Oppenheimer

$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences downgraded to Perform from Outperform at OppenheimerVentyx Biosciences downgraded to Perform from Outperform at Oppenheimer

Michael Yee

UBS

$20→$14

Hold

1.16%

Upside

Downgraded

01/08/26

Ventyx Biosciences initiated with a Buy at UBSVentyx Biosciences initiated with a Buy at UBS

Sam Slutsky

LifeSci Capital

$14

Hold

1.16%

Upside

Downgraded

01/07/26

Hold Rating on Ventyx Biosciences Reflects Limited Upside Amid Eli Lilly All‑Cash Acquisition at $14 per Share

Alex Thompson CFA

Stifel Nicolaus

Hold

-34.97%

Downside

Assigned

01/07/26

Hold Rating Maintained on Eli Lilly’s Acquisition of Ventyx Biosciences Amid Limited Upside and NLRP3 Uncertainty

Kaveri Pohlman

Clear Street

$11

Buy

-20.52%

Downside

Initiated

09/30/25

Clear Street Initiates a Buy Rating on Ventyx Biosciences (VTYX)

Vikram Purohit

Morgan Stanley

Hold

―

Reiterated

06/17/25

Hold Rating for Ventyx Biosciences Amid Promising Early Data and Strategic Uncertainties

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ventyx Biosciences

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+181.30%

initiated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +181.30% per trade.

1 Year

Kaveri PohlmanClear Street

Success Rate

1/1 ratings generated profit

Average Return

+345.00%

initiated a buy rating 4 months ago

Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +345.00% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+345.00%

initiated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +345.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VTYX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VTYX has received 9 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. VTYX average Analyst price target in the past 3 months is 13.38.

Each month's total comprises the sum of three months' worth of ratings.

VTYX Financial Forecast

VTYX Earnings Forecast

Next quarter’s earnings estimate for VTYX is -$0.37 with a range of -$0.49 to -$0.29. The previous quarter’s EPS was -$0.32. VTYX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VTYX has Performed in-line its overall industry.

No data currently available

VTYX Sales Forecast

Next quarter’s sales forecast for VTYX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VTYX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VTYX has Performed in-line its overall industry.

VTYX Stock Forecast FAQ

What is VTYX’s average 12-month price target, according to analysts?

Based on analyst ratings, Ventyx Biosciences, Inc.’s 12-month average price target is 13.38.

What is VTYX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for VTYX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VTYX a Buy, Sell or Hold?

Ventyx Biosciences, Inc. has a consensus rating of Hold which is based on 0 buy ratings, 8 hold ratings and 0 sell ratings.

What is Ventyx Biosciences, Inc.’s price target?

The average price target for Ventyx Biosciences, Inc. is 13.38. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $9.00. The average price target represents -3.32% Decrease from the current price of $13.84.

What do analysts say about Ventyx Biosciences, Inc.?

Ventyx Biosciences, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of VTYX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ventyx Biosciences (VTYX) Stock Forecast & Price Target

VTYX Analyst Ratings

VTYX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ventyx Biosciences

VTYX Analyst Recommendation Trends

VTYX Financial Forecast

VTYX Earnings Forecast

VTYX Sales Forecast

VTYX Stock Forecast FAQ

Detailed List of Analyst Forecasts